Lisbeth Evered1, Brendan Silbert, David A Scott, David Ames, Paul Maruff, Kaj Blennow. 1. From the Centre for Anaesthesia and Cognitive Function, Department of Anaesthesia and Acute Pain Medicine, St. Vincent's Hospital, and Anaesthesia, Perioperative, and Pain Medicine Unit, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia (L.E., B.S., D.A.S.); Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, and National Ageing Research Institute, Parkville, Victoria, Australia (D.A.); Florey Institute for Neuroscience and Mental Health, Parkville, Victoria, Australia (P.M.); and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Gothenburg, Sweden (K.B.).
Abstract
BACKGROUND: Postoperative cognitive dysfunction (POCD) affects 16 to 21% of the elderly 3 months after anesthesia and surgery and is associated with adverse outcomes. The exact cause of POCD remains unknown. The authors hypothesized that elderly individuals with Alzheimer disease (AD) neuropathology, identified by cerebrospinal fluid (CSF) analysis, would have increased the risk for POCD. METHODS: CSF samples were collected from 59 patients 60 yr or older who received combined spinal and general anesthesia for elective total hip replacement. Patients underwent neuropsychological testing preoperatively and at 7 days, 3 months, and 12 months postoperatively. POCD at 3 months and cognitive decline at 12 months were calculated by using the reliable change index. CSF amyloid β1-42 (Aβ1-42), total-tau, phosphorylated-tau, and neurofilament light were assayed with enzyme-linked immunosorbent assay methods. RESULTS: POCD was identified in 5 of 57 patients (8.8%) at 3 months. For Aβ1-42, 11 patients were below the cut-point for AD neuropathology of whom 3 were classified with POCD (27.3%; 95% CI, 6.0 to 61%), whereas of the 46 patients above the cut-point, 2 were classified with POCD (4.3%; 95% CI, 0.5 to 14.8%) (P = 0.01). There was no significant difference in the incidence of POCD in relation to the cut-points for any of the other analytes. CONCLUSIONS: Low CSF Aβ1-42 may be a significant predictor of POCD at 3 months. This indicates that patients with AD neuropathology even in the absence of clinically detectable AD symptoms may be susceptible to POCD.
BACKGROUND:Postoperative cognitive dysfunction (POCD) affects 16 to 21% of the elderly 3 months after anesthesia and surgery and is associated with adverse outcomes. The exact cause of POCD remains unknown. The authors hypothesized that elderly individuals with Alzheimer disease (AD) neuropathology, identified by cerebrospinal fluid (CSF) analysis, would have increased the risk for POCD. METHODS: CSF samples were collected from 59 patients 60 yr or older who received combined spinal and general anesthesia for elective total hip replacement. Patients underwent neuropsychological testing preoperatively and at 7 days, 3 months, and 12 months postoperatively. POCD at 3 months and cognitive decline at 12 months were calculated by using the reliable change index. CSF amyloid β1-42 (Aβ1-42), total-tau, phosphorylated-tau, and neurofilament light were assayed with enzyme-linked immunosorbent assay methods. RESULTS:POCD was identified in 5 of 57 patients (8.8%) at 3 months. For Aβ1-42, 11 patients were below the cut-point for AD neuropathology of whom 3 were classified with POCD (27.3%; 95% CI, 6.0 to 61%), whereas of the 46 patients above the cut-point, 2 were classified with POCD (4.3%; 95% CI, 0.5 to 14.8%) (P = 0.01). There was no significant difference in the incidence of POCD in relation to the cut-points for any of the other analytes. CONCLUSIONS: Low CSF Aβ1-42 may be a significant predictor of POCD at 3 months. This indicates that patients with AD neuropathology even in the absence of clinically detectable AD symptoms may be susceptible to POCD.
Authors: Miles Berger; Niccolò Terrando; S Kendall Smith; Jeffrey N Browndyke; Mark F Newman; Joseph P Mathew Journal: Anesthesiology Date: 2018-10 Impact factor: 7.892
Authors: Elizabeth Mahanna-Gabrielli; Katie J Schenning; Lars I Eriksson; Jeffrey N Browndyke; Clinton B Wright; Deborah J Culley; Lis Evered; David A Scott; Nae Yah Wang; Charles H Brown; Esther Oh; Patrick Purdon; Sharon Inouye; Miles Berger; Robert A Whittington; Catherine C Price; Stacie Deiner Journal: Br J Anaesth Date: 2019-08-19 Impact factor: 9.166
Authors: Christopher R Carpenter; Frances McFarland; Michael Avidan; Miles Berger; Sharon K Inouye; Jason Karlawish; Frank R Lin; Edward Marcantonio; John C Morris; David B Reuben; Raj C Shah; Heather E Whitson; Sanjay Asthana; Joe Verghese Journal: J Am Geriatr Soc Date: 2019-08-22 Impact factor: 5.562
Authors: Rebecca Y Klinger; Olga G James; Salvador Borges-Neto; Tiffany Bisanar; Yi-Ju Li; Wenjing Qi; Miles Berger; Niccolò Terrando; Mark F Newman; P Murali Doraiswamy; Joseph P Mathew Journal: Anesthesiology Date: 2018-04 Impact factor: 7.892
Authors: Stacie Deiner; Mark G Baxter; Joshua S Mincer; Mary Sano; James Hall; Ismail Mohammed; Sid O'Bryant; Henrik Zetterberg; Kaj Blennow; Roderic Eckenhoff Journal: Br J Anaesth Date: 2020-06-11 Impact factor: 9.166
Authors: Keith W VanDusen; Sarada Eleswarpu; Eugene W Moretti; Michael J Devinney; Donna M Crabtree; Daniel T Laskowitz; Marty G Woldorff; Kenneth C Roberts; John Whittle; Jeffrey N Browndyke; Mary Cooter; Frank W Rockhold; Oke Anakwenze; Michael P Bolognesi; Mark E Easley; Michael N Ferrandino; William A Jiranek; Miles Berger Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472